Digestive and Surgical Oncology Department, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, 2 rue Ambroise-Paré, 75010, Paris, France.
Department of Pathology, Lariboisière Hospital, Assistance publique-Hôpitaux de Paris, 2 rue Ambroise-Paré, 75010, Paris, France.
Dig Liver Dis. 2017 Aug;49(8):924-928. doi: 10.1016/j.dld.2017.05.017. Epub 2017 May 30.
The interval between surgery and adjuvant chemotherapy (AC) is a predictive factor of survival in high-risk colon cancer (CC). This study aimed to evaluate the impact of intraoperative sentinel lymph node (SLN) analysis using the one-step nucleic acid amplification (OSNA) technique on the time interval between surgery and AC.
We performed a prospective study analyzing 56 consecutive patients who had surgery for CC between July 2012 and October 2014, including 20 patients needing AC. SLN status was determined intraoperatively in 17 patients in the OSNA group; when positive, a portacath (PAC) was placed during the procedure for upcoming AC. In the remaining patients, we proceeded without SLN status determination and the PAC was installed after definitive histopathological analysis of the specimen if needed.
There was no difference between the groups regarding cancer staging, duration of hospitalization (7.5days in the OSNA group and 10days in the control group, p=0.43) and major complications (20% vs 30% respectively, p=0.55). The time interval between surgery and adjuvant chemotherapy was significantly shorter in the OSNA group at 35 (±8) days vs 67 (±36) days (p=0.021).
SLN status determination by the OSNA technique is safe, feasible and could significantly reduce time between surgery and adjuvant chemotherapy in a pilot study.
手术和辅助化疗(AC)之间的间隔是高危结肠癌(CC)生存的预测因素。本研究旨在评估使用一步式核酸扩增(OSNA)技术进行术中前哨淋巴结(SLN)分析对手术和 AC 之间时间间隔的影响。
我们进行了一项前瞻性研究,分析了 2012 年 7 月至 2014 年 10 月期间接受 CC 手术的 56 例连续患者,其中包括 20 例需要 AC 的患者。在 OSNA 组的 17 名患者中,术中确定了 SLN 状态;如果阳性,术中放置了端口导管(PAC),以备后续进行 AC。在其余患者中,我们在没有确定 SLN 状态的情况下进行操作,如果需要,在对标本进行明确的组织病理学分析后,再安装 PAC。
两组之间在癌症分期、住院时间(OSNA 组为 7.5 天,对照组为 10 天,p=0.43)和主要并发症(分别为 20%和 30%,p=0.55)方面无差异。OSNA 组手术和辅助化疗之间的时间间隔明显缩短,为 35(±8)天比 67(±36)天(p=0.021)。
在一项试点研究中,OSNA 技术确定 SLN 状态是安全、可行的,并可显著缩短手术和辅助化疗之间的时间间隔。